AviadoBio Pioneering genetic therapies for neurodegenerative disease Neurological disease remains the largest cause of disability and second leading cause of mortality, worldwide, but life-changing therapies could be on the horizon.
Denali Therapeutics Neurodegenerative disease has remained an undefeated adversary for too long. That needed to change. Through our affiliate FBRI, F-Prime has had a long-standing commitment to cure neurodegenerative diseases. But all previous disease-modifying trials in this arena had failed. In the past decade, though, major scientific insights into the underlying genetic causes and biological processes—along with new translational medicine tools—gave us hope for a different future.
Flywire While preparing to attend MIT in 2008, an international student was tasked with sending his international tuition payment to the university- but the entire process lacked transparency.
K36 Therapeutics K36 Therapeutics: Advancing a first-in-class MMSET inhibitor to benefit t(4;14) multiple myeloma patients and beyond F-Prime has long been interested in precision medicine approaches that tackle the underlying cause of diseases, ranging from investments in small molecules (e.g., Blueprint Medicines) to gene editing technologies (e.g., Beam Therapeutics).
Orchard Therapeutics Prof. Bobby Gaspar wanted to solve a big puzzle. But he only had a few pieces in hand. He and his co-founders had some of the most exciting-edge gene therapy medicines-and clinical data showing they worked-but that wasn't enough.
PatientPing Patients get care from many providers. When these caregivers don’t coordinate, it’s dangerous and expensive. Could this be improved by solving a communication problem?
Project Beacon As COVID-19 rapidly spread across the Commonwealth of Massachusetts a year ago now, it quickly grew apparent to Boston’s life science community that there was a dire need for efficient, affordable, accessible and equitable testing.
Toast From the willingness to listen and the ability to innovate in the face of failure, a Boston unicorn is born. Steve, Aman and Jon were at dinner when they realized the restaurant industry needed a serious tech upgrade. The three MIT grads had met at enterprise software company Endeca, and had been thinking of starting their own company in the mobile commerce space.
Ultragenyx Emil Kakkis has always been driven to solve difficult problems. When he approached us, he was looking for an investor who would understand rare diseases the way he did. His vision was to build a mission-driven company to treat rare and ultra-rare genetic diseases—all the way from concept to globally-approved drugs.
